natgillin/translations-raw huggingface dataset:
In the all-randomised population, tests for difference of capecitabine vs 5-FU/LV in disease-free and overall survival showed hazard ratios of 0.88 (95% CI 0.77 – 1.01; p = 0.068) and 0.86 (95% CI 0.74 – 1.01; p = 0.060), respectively.
V celotni randomizirani populaciji so analize zdravljenja s kapecitabinom v primerjavi s 5-FU/LV v preživetju brez bolezni pokazale razmerje ogroženosti 0,88 (95-% interval zaupanja 0,77−1,01; p = 0,068), v celokupnem preživetju pa 0,86 (95-% interval zaupanja 0,74−1,01; p = 0,060).
In the alternating treatment study, the treatment schedule combining Ferriprox for five days with deferoxamine for two days reduced blood ferritin levels to the same extent as deferoxamine taken on its own.
V študiji zdravljenja z izmenjevanjem zdravil je urnik zdravljenja, po katerem so kombinirali pet dni zdravljenja z zdravilom Ferriprox in dva dni z deferoksaminom, znižal ravni feritina v krvi v enaki meri kot zdravljenje samo z deferoksaminom.
In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.
V študiji AMPLIFY je bilo skupno 5.395 bolnikov randomiziranih v skupino, ki je prejemala 7- dnevno zdravljenje z apiksabanom 10 mg peroralno dvakrat na dan, čemur je sledilo 6-mesečno jemanje 5 mg apiksabana peroralno dvakrat na dan, ali v skupino, ki je prejemala 1 mg/kg enoksaparina subkutano dvakrat na dan vsaj 5 dni (dokler ni bil INR  2) in varfarin (ciljno območje INR 2,0-3,0) peroralno 6 mesecev.
In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.
V študiji AMPLIFY-EXT je bilo 2.482 bolnikov randomiziranih v skupine, ki so 12 mesecev prejemale apiksaban 2,5 mg peroralno dvakrat na dan, apiksaban 5 mg peroralno dvakrat na dan ali placebo, in sicer po koncu od 6- do 12-mesečnega prvotnega antikoagulacijskega zdravljenja.
In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were 3.4 (95% CI 1.4 - 8.5) with celecoxib 400 mg twice daily and 2.8 (95% CI 1.1 - 7.2) with celecoxib 200 mg twice daily.
V preskušanju APC je bilo relativno tveganje za sestavljeni opazovani dogodek (presojeno) srčnožilne smrti, miokardnega infarkta ali možganske kapi v primerjavi s placebom pri celekoksibu 400 mg dvakrat na dan 3,4 (95 % IZ: 1,4–8,5) in pri celekoksibu 200 mg dvakrat na dan in 2,8 (95 % IZ: 1,1– 7,2.
In the Aranesp group, 83% were receiving dialysis and 17% were not receiving dialysis.
V skupini, ki je dobivala zdravilo Aranesp, je bilo 83 % bolnikov na dializi, 17 % pa ne.
In the arcuate nucleus of the hypothalamus, bupropion stimulates pro-opiomelanocortin (POMC) neurons that release alpha-melanocyte stimulating hormone (α-MSH), which in turn binds to and stimulates melanocortin 4 receptors (MC4-R).
V arkuatnem jedru hipotalamusa bupropion stimulira nevrone proopiomelanokortina (POMC), ki sproščajo alfa-melanocite stimulirajoči hormon (α-MSH), ki se ponovno veže na in stimulira receptorje melanokortina 4 (MC4-R).
In the ARISTOTLE study a total of 18,201 patients were randomised to double-blind treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [4.7%], see section 4.2) or warfarin (target INR range 2.0-3.0), patients were exposed to study drug for a mean of 20 months.
V študiji AVERROES je bilo skupno 5.598 bolnikov, za katere so bili raziskovalci mnenja, da pri njih zdravljenje z antagonisti vitamina K (AVK) ni primerno, randomiziranih v skupino, ki se je zdravila z apiksabanom v odmerku 5 mg dvakrat na dan (oziroma 2,5 mg dvakrat na dan pri izbranih bolnikih [6,4 %], glejte poglavje 4.2), oziroma skupino, ki se je zdravila z acetilsalicilno kislino.
In the AS001 clinical trial, Cimzia-treated patients reported significant improvements in physical function as assessed by the BASFI and in pain as assessed by the Total and Nocturnal Back Pain NRS scales as compared to placebo.
V primerjavi s placebom so bolniki pri AS001 kliničnem preskušanju, ki so se zdravili z zdravilom Cimzia, poročali o značilnih izboljšanjih telesnih funkcij, ocenjeno z BASFI, in značilnih izboljšanjih bolečine, ocenjeno s številčno lestvico (NRS) za celostno in nočno bolečino v križu.
In the available clinical data, the effect on LDL-C reduction was not considered to be significantly different to simvastatin monotherapy when LDL-C is controlled at the time of initiating treatment.
Pri razpoložljivih kliničnih podatkih učinek na znižanje LDL-holesterola ni bil pomembno drugačen od monoterapije s simvastatinom, po tem ko je bil LDL-holesterol pred uvedbo zdravljenja s kombinacijo obvladan.
In the Bangladesh field trial, protective efficacy of Dukoral in the overall population was 85% (95%CI: 56, 95, per-protocol analysis) for the initial 6 months of follow-up.
V terenskem preskušanju v Bangladešu je bila v prvih 6 mesecih sledenja učinkovitost zaščite Dukorala v celotni populaciji 85-odstotna (interval zaupanja 95 %: 56, 95, analiza po protokolih).
In the BCIRG 006 study HER2 positive, EBC was defined as either lymph node positive or high risk node negative patients with no (pN0) lymph node involvement, and at least 1 of the following factors: tumour size greater than 2 cm, estrogen receptor and progesterone receptor negative, histological and/or nuclear grade 2-3, or age < 35 years.
V preskušanju BCIRG 006 je bil HER2-pozitiven zgodnji rak dojk omejen bodisi na bolnike s pozitivnimi bezgavkami bodisi na bolnike z negativnimi bezgavkami z visokim tveganjem (brez prizadetih bezgavk (pN0) in z vsaj enim od naslednjih faktorjev: tumor, večji od 2 cm, negativni estrogenski in progesteronski receptorji, histološki in/ali jedrni gradus 2 do 3 ali starost < 35 let).
In the BCIRG 006 study Herceptin was administered either in combination with docetaxel, following AC chemotherapy (AC→DH) or in combination with docetaxel and carboplatin (DCarbH).
V študiji BCIRG 006 so zdravilo Herceptin dajali v kombinaciji z docetakselom po kemoterapiji z doksorubicinom in ciklofosfamidom (AC → DH) ali v kombinaciji z docetakselom in karboplatinom (DCarbH).
In the Betaferon pack you will find:
Zavoj zdravila Betaferon vsebuje:
In the body, 5-FU takes the place of pyrimidine and interferes with the enzymes involved in making new DNA.
5- fluorouracil v telesu zavzame mesto pirimidina in ovira encime, ki sodelujejo pri tvorjenju nove DNK.
In the body, 6–mercaptopurine is converted within cells into a substance that interferes with the production of new DNA.
V telesu se 6-merkaptopurin znotraj celic pretvori v učinkovino, ki ovira nastanek nove DNK.
In the body, a hormone called ‘thrombopoietin’ stimulates the production of platelets by attaching to certain receptors in the bone marrow.
V telesu nastajanje trombocitov spodbuja hormon trombopoetin, tako da se veže na določene receptorje v kostnem mozgu.
In the body, a hormone called ‘thrombopoietin’ stimulates the production of platelets in the bone marrow.
V telesu nastajanje trombocitov v kostnem mozgu spodbuja hormon, imenovan „trombopoetin“.
In the body, everolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex’.
Everolimus se v telesu najprej veže na beljakovino v celicah, imenovano FKBP-12, in z njo tvori „skupek“.
In the body, factor VII is involved in blood clotting.
Faktor VII v telesu sodeluje pri koagulaciji (strjevanju) krvi.
In the body, FSH stimulates the production of eggs, and LH stimulates their release.
V telesu FSH spodbuja nastajanje jajčec, LH pa spodbuja njihovo sproščanje.
In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’.
V telesu se pretvori v mikofenolno kislino, ki zavira encim, imenovan „inozin monofosfat- dehidrogenaza“.
In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’.
V telesu se pretvori v mikofenolno kislino, ki zavira encim, imenovan „inozin monofosfat-dehidrogenaza“.
In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’.
Zdravilo se v telesu pretvori v mikofenolno kislino, ki zavira encim inozin-monofosfat-dehidrogenaza.
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells).
Pemetreksed se v telesu pretvori v aktivno obliko, ki zavira aktivnost encimov, ki sodelujejo pri tvorbi „nukleotidov“ (gradnikov DNK in RNK, genskega materiala celic).
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells).
V telesu se pemetreksed pretvori v aktivno obliko, ki zavira aktivnost encimov, vključenih v tvorbo nukleotidov (gradnikov DNK in RNK, genskega materiala celic).
In the body, protein C controls the generation of thrombin, one of the substances (factors) involved in blood clotting.
V telesu protein C nadzoruje tvorbo trombina, t.j. ene od snovi (faktorjev), ki sodelujejo pri strjevanju krvi.
In the body, radium is handled like the calcium naturally found in the bones.
Radij v telesu deluje na enak način kot kalcij, ki je naravno prisoten v kosteh.
In the body, sirolimus attaches to a protein that is found inside cells to make a ‘complex’.
Sirolimus se v telesu veže na beljakovino v celicah in tako ustvari skupek.
In the body, temsirolimus attaches to a protein that is found inside cells to make a ‘complex’.
Temsirolimus se v telesu veže na beljakovino, ki jo vsebujejo celice, in tako ustvari skupek.
In the body, trifluridine is converted into an active form that is incorporated directly into DNA, the genetic material of cells.
Trifluridin se v telesu pretvori v aktivno obliko, ki se vgradi neposredno v DNA, genetski material celic.
In the BR-CAP group, 22.5% of patients received platelet transfusions compared to 2.9% of patients in the R-CHOP group.
V skupini BR-CAP je prejelo infuzijo trombocitov 22,5% bolnikov, v skupini R-CHOP pa 2,9% bolnikov.
In the brain GABA is involved in reducing the electrical activity.
GABA sodeluje pri zmanjševanju električne dejavnosti v možganih.
In the brain it stimulates receptors for GABA, a substance involved in reducing electrical activity in the brain.
V možganih stimulira receptorje gama-aminomaslene kisline, GABA, tj. snovi, ki sodeluje pri zniževanju električne dejavnosti v možganih.
In the breast cancer study, patients who took Afinitor lived for an average of 7.8 months without their disease getting worse, compared with 3.2 months for the patients who took placebo.
V študiji raka dojke so bolniki, ki so prejemali zdravilo Afinitor, v povprečju 7,8 meseca živeli brez poslabšanja bolezni v primerjavi s 3,2 meseca pri bolnikih, ki so prejemali placebo.
In the BTDx group 12% of patients were cytogenetically classified as high risk versus 16% of patients in the TDx group.
V skupini BTDx je imelo 12% bolnikov citogenetiko visokega tveganja v primerjavi s 16% v skupini TDx.
In the burn wound study with 61 patients, the mean study wound area was 216 cm2; the total burn injury of these patients was larger and affected 5.8% of the total body surface area.
Pri študiji opeklin z 61 bolniki je bila povprečna velikost rane, pri bolnikih, ki so bili vključeni v študijo, 216 cm2; celotne opekline teh bolnikov so bile večje in so prizadele 5,8 % celotne površine telesa.
In the C-SURFER study, overall SVR was achieved in 94 % (115/122) of subjects receiving EBR + GZR for 12 weeks.
V študiji C-SURFER je skupno SVR doseglo 94 % (115/122) preiskovancev, ki so 12 tednov prejemali EBR + GZR.
In the C211 Phase 3 clinical trial, there was no difference in the type of emerging variants between patients receiving telaprevir 1,125 mg twice daily (b.i.d.) and patients receiving telaprevir 750 mg every 8 hours (q8h).
V kliničnem preskušanju faze III (C211) ni bilo razlik v pojavu za telaprevir rezistentnih variant med bolniki, ki so prejemali 1.125 mg telaprevirja dvakrat na dan in bolniki, ki so prejemali 750 mg telaprevirja na 8 ur.
In the CAP-001 studies the probability of remaining undelivered and not requiring alternative tocolytics within 7 days of treatment initiation was similar for atosiban and beta-mimetics treated women at gestational age of 24-28 weeks.
Verjetnost, da ne pride do poroda in da v 7 dneh od začetka zdravljenja niso potrebni alternativni tokolitiki, je bila v študijah CAP-001 pri ženskah, zdravljenih v obdobju od 24. do 28. tedna gestacije, pri uporabi atosibana podobna kot pri uporabi beta-mimetikov.
In the case both vaccines are used at the same day the size of the local reactions may increase up to 6 cm in individual pigs and may last 5 weeks.
V primeru, da se obe cepivi uporabita na isti dan, se lahko velikost lokalnih reakcij pri posameznih prašičih poveča do 6 cm in lahko traja 5 tednov.
In the case excess Macugen volume is injected, serious increase in intraocular pressure may occur.
V primeru, da vam je bil injiciran presežni volumen zdravila Macugen, se lahko pojavi zvišanje očesnega tlaka.
In the case of a previously treated oesophageal segment, if it has not sufficiently healed and/or histological assessment of biopsies is not clear, the subsequent course of PDT may be delayed for an additional 1-2 months.‌‌‌
V primeru predhodno zdravljenega segmenta požiralnika, kadar ni bil dovolj ozdravljen, in/ali če histološka ocena opravljenih biopsij ni jasna, se lahko naslednja epizoda PDT prestavi še za 1-2 meseca.
In the case of accidental ingestion by a person, seek medical advice immediately and show the package leaflet or the label to the physician.
Če kdo nenamerno zaužije zdravilo, mora takoj poiskati zdravniško pomoč in zdravniku pokazati navodilo za uporabo ali oznako na ovojnini.
In the case of accidental ingestion, particularly in the case of children, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
V primeru nenamernega zaužitja je treba takoj poiskati zdravniško pomoč, zlasti če gre za otroke, in zdravniku pokazati navodilo za uporabo ali nalepko.
In the case of accidental self injection, seek medical advice immediately and show the package insert or label to a physician.
V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
In the case of accidental self –injection, headache, bone and muscle pain may occur.
V primeru nenamernega samoinjiciranja se lahko pojavijo glavobol ter bolečine v kosteh in mišicah.
In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician.
V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
In the case of adrenal insufficiency and depending on the severity of the event, the dose of Ketoconazole HRA should be decreased by at least 200 mg/day or the treatment should be temporarily discontinued and/or a corticosteroid therapy should be added until the resolution of the event.
Če pride do adrenalne insuficience, je treba glede na resnost dogodka odmerek zdravila Ketokonazol HRA zmanjšati za vsaj 200 mg/dan ali zdravljenje začasno prekiniti in/ali dodati zdravljenje s kortikosteroidi, dokler dogodek ne izzveni.
In the case of adverse clinical signs, treat symptomatically.
V primeru neželenih kliničnih znakov zdravite simptomatsko.
In the case of adverse reactions such as dizziness, which has been reported with leflunomide, the parent compound, the patient’s ability to concentrate and to react properly may be impaired.
V primeru neželenih učinkov, kot je omotica, o kateri so poročali pri uporabi leflunomida, starševske spojine, je lahko bolnikova sposobnost koncentracije in ustrezne reakcije zmanjšana.
In the case of adverse reactions, doses might be reduced to once daily doses of 9 mg/kg bodyweight (range 7.5–10.5 mg/kg) or 6 mg/kg bw (range 4.5–7.5 mg/kg) according to the tables below.
V primeru neželenih reakcij je odmerke mogoče zmanjšati na enkrat dnevno 9 mg/kg telesne mase (razpon 7,5 – 10,5 mg/kg) ali 6 mg/kg telesne mase (razpon 4,5 – 7,5) v skladu s spodnjimi tabelami.
In the case of an adverse reaction, immediate withdrawal of medication is recommended.
V primeru pojava neželenih učinkov je priporočljivo takoj prenehati z zdravljenjem.
In the case of an increase in liver enzymes equal to or greater than 3 times the upper limit of normal, Ketoconazole HRA should be stopped immediately and should not be reintroduced due to the risk of serious hepatic toxicity.
Če je povečanje vrednosti jetrnih encimov večje od trikratne zgornje meje normalnih vrednosti, je treba uporabo zdravila Ketokonazol HRA takoj prekiniti in se ne sme ponovno uvesti, saj obstaja tveganje resne jetrne toksičnosti.
In the case of an overdose hypotensive/vasovagal reaction might be anticipated as well as headache, flushing, nausea, vomiting, and diarrhoea.
Če pride do prevelikega odmerjanja, se lahko pojavijo hipotenzivne/vazovagalne reakcije kot tudi glavobol, pordevanje, navzea, bruhanje in driska.
In the case of associated clinical symptoms of liver injury, i.e., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever), treatment must be stopped and re-introduction of STAYVEER is not to be considered.
V primeru kliničnih simptomov, povezanih z okvarjenim delovanjem jeter, npr. slabost, bruhanje, povišana telesna temperatura, bolečine v trebuhu, zlatenica, nenavadna letargija ali utrujenost, gripi podobni simptomi (bolečine v sklepih, bolečine v mišicah, povišana telesna temperatura), moramo zdravljenje prekiniti in ponovna uvedba zdravljenja z zdravilom STAYVEER ni dovoljena.
In the case of associated clinical symptoms of liver injury, i.e., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever), treatment must be stopped and re-introduction of Tracleer is not to be considered.
V primeru kliničnih simptomov, povezanih z okvarjenim delovanjem jeter, npr. slabost, bruhanje, povišana telesna temperatura, bolečine v trebuhu, zlatenica, nenavadna letargija ali utrujenost, gripi podobni simptomi (bolečine v sklepih, bolečine v mišicah, povišana telesna temperatura), moramo zdravljenje prekiniti in ponovna uvedba zdravljenja z zdravilom Tracleer ni dovoljena.
In the case of bleeding, dose interruptions, adjustments, or discontinuation may be necessary (see section 4.2).
V primeru krvavitve bodo morda potrebne prekinitve, prilagoditve ali ukinitev odmerjanja (glejte poglavje 4.2).
In the case of bleeding, please contact your doctor before stopping the intake of Pradaxa®.
Če se pojavi krvavitev, se posvetujte z zdravnikom, preden boste prenehali jemati zdravilo Pradaxa®.
In the case of clinical deterioration (e.g., decrease in 6-minute walk test distance by at least 10% compared with pre-treatment measurement) despite STAYVEER treatment for at least 8 weeks (target dose for at least 4 weeks), alternative therapies should be considered.
V primeru poslabšanja kliničnega stanja (denimo, zmanjšanje prehojene razdalje v 6-minutnem preskusu s hojo za vsaj 10 % v primerjavi z rezultatom pred začetkom zdravljenja) kljub 8-tedenskemu zdravljenju z zdravilom STAYVEER (ciljni odmerek uporabljan vsaj 4 tedne) razmislimo o drugačnih možnostih zdravljenja.
In the case of combination therapy with Pegasys and ribavirin, please follow the dosing regimen recommended by your doctor.
Pri kombiniranem zdravljenju z zdravilom Pegasys in ribavirinom upoštevajte odmerjanje, ki vam ga je predpisal zdravnik.
In the case of combination therapy with Pegasys, please follow the dosing regimen recommended by your doctor and refer also to the package leaflets of any other medicines that are used in combination with Pegasys.
Pri kombiniranem zdravljenju z zdravilom Pegasys, prosimo, upoštevajte odmerjanje, ki vam ga je predpisal zdravnik, in glejte tudi navodila za uporabo zdravil, ki jih jemljete v kombinaciji z zdravilom Pegasys.
In the case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
Pri sočasnem protivirusnem zdravljenju zaradi hepatitisa B ali C preberite tudi pomembne informacije o teh zdravilih.
In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.
V primeru, da sočasno pride do mikrobne bolezni ali parazitske infestacije, je treba psa na ustrezen način zdraviti proti tej bolezni.
In the case of increase of liver enzymes levels above 3 times the upper limit of normal, Ketoconazole HRA should be stopped immediately and should not be reintroduced because of the risk of serious hepatic toxicity.
Če se ravni jetrnih encimov zvišajo na več kot trikratno zgornjo mejo normalnih vrednosti, je treba jemanje zdravila Ketokonazol HRA takoj prekiniti in ga ni dovoljeno ponovno uvesti zaradi tveganja resne jetrne toksičnosti.
In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.
V primeru intravenskega dajanja pri mačkah se lahko pojavijo izrazitejši neželeni učinki npr. hipertermija, mehko blato, anoreksija, zmanjšanje pitja in kolaps.
In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.
V primeru intravenskega dajanja pri mačkah se lahko pojavijo izrazitejši neželeni učinki npr. hipertermija, mehko blato, anoreksija, zmanjšano pitje in kolaps.
In the case of iron-induced heart failure, Ferriprox at 75-100 mg/kg/day should be added to deferoxamine therapy.
V primeru srčnega popuščanja zaradi železa je treba terapiji z deferoksaminom dodati zdravilo Ferriprox 75–100 mg/kg/dan.
In the case of late clinical deterioration despite treatment with STAYVEER (i.e., after several months of treatment), the treatment should be re-assessed.
V primeru kasnejšega poslabšanja kliničnega stanja kljub zdravljenju z zdravilom STAYVEER (tj. po nekaj mesecih zdravljenja) je treba zdravljenje ponovno oceniti.
In the case of late clinical deterioration despite treatment with Tracleer (i.e., after several months of treatment), the treatment should be re-assessed.
V primeru kasnejšega poslabšanja kliničnega stanja kljub zdravljenju z zdravilom Tracleer (tj. po nekaj mesecih zdravljenja) je treba zdravljenje ponovno oceniti.
In the case of major surgical interventions in particular, a precise monitoring of the substitution therapy by means of coagulation analysis (plasma FVIII activity) is indispensable.
Še zlasti pri velikih kirurških posegih je skrbno spremljanje nadomestnega zdravljenja z analizo koagulacije (aktivnosti FVIII v plazmi) nepogrešljivo.
In the case of major surgical interventions in particular, precise monitoring of substitution therapy by means of coagulation analysis (plasma factor IX activity) is indispensable.
Posebno v primeru večjih kirurških posegov je natančno spremljanje nadomestnega zdravljenja s pomočjo analize strjevanja krvi (aktivnosti faktorja IX v plazmi) nujno potrebno.
In the case of over dosage symptomatic treatment should be initiated.
Pri prevelikem odmerjanju uvedemo simptomatsko zdravljenje.
In the case of overdosage symptomatic treatment should be initiated.
Pri nenamernem vnosu prevelikega odmerka uvedemo simptomatsko zdravljenje.
In the case of overdosage, seek medical advice.
Pri nenamernem vnosu prevelikega odmerka uvedemo simptomatsko zdravljenje.